Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Shortened CAPOX regimen appears effective in stage II colorectal cancer

Publish date:: February 13, 2020

Key clinical point: For patients with high-risk stage II colorectal cancer, 3 months of adjuvant therapy with capecitabine plus oxaliplatin (CAPOX) may be as effective as a 6-month regimen, but with fewer adverse events.

Major finding: Five-year relapse-free survival rates were similar in patients who received 3 months of CAPOX and those who received 6 months of CAPOX, with a 0.76% difference favoring the 6-month arm.

Study details: TOSCA was a phase 3 noninferiority trial of 1,254 patients with high-risk stage II resected colorectal cancer.

Disclosures: The study was funded by the Italian Group for the Study of Digestive Tract Cancers (GISCAD) Foundation and Agenzia Italiana del Farmaco. The investigators disclosed relationships with Servier, Merck, Bristol-Myers Squibb, and other companies.

Citation:

Petrelli F et al. JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6486.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,